IL2 and COVID-19: In addition, the dynamic trajectories of serum inflammatory factors, including CRP, IL-6, IL-2, and tumor necrosis factor-alpha (TNF-α), have demonstrated lower degrees of elevation in the hospitalized COVID-19 patients with metformin treatment than the non-metformin group, particularly in patients with severe COVID-1925.